Persistence sometimes pays off in drug development, as Daiichi Sankyo might soon find out. Two years after the FDA kicked out a filing for Vanflyta in relapsed/refractory AML, the drug’s front-line AML study, Quantum-First, has read out positively for overall survival.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,